Cleared Traditional

NEW SUPER POLI-GRIP DENTURE ADHESIVE CREAM (K862876) - FDA 510(k) Clearance

Class I Dental device.

K862876 · Block Drug Company, Inc. · Dental device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1986
Decision
30d
Days
Class 1
Risk

K862876 is an FDA 510(k) clearance for the NEW SUPER POLI-GRIP DENTURE ADHESIVE CREAM. Classified as Adhesive, Denture, Polyvinyl Methylether Maleic Acid Calcium-sodium Double Salt (product code KOO), Class I - General Controls.

Submitted by Block Drug Company, Inc. (Jersey City, US). The FDA issued a Cleared decision on August 29, 1986 after a review of 30 days - a notably fast clearance cycle.

This device falls under the Dental FDA review panel, regulated under 21 CFR 872.3490 - the FDA dental device regulatory framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Block Drug Company, Inc. devices

Submission Details

510(k) Number K862876 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 30, 1986
Decision Date August 29, 1986
Days to Decision 30 days
Submission Type Traditional
Review Panel Dental (DE)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
97d faster than avg
Panel avg: 127d · This submission: 30d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KOO Adhesive, Denture, Polyvinyl Methylether Maleic Acid Calcium-sodium Double Salt
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 872.3490
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.